Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:DYN News 9 December 2025 - 4 January 2026

Dyne Therapeutics stock drops 5% into 2026 — FDA filing timeline and next earnings date in focus

Dyne Therapeutics stock drops 5% into 2026 — FDA filing timeline and next earnings date in focus

NEW YORK, January 4, 2026, 13:49 ET — Market closed Dyne Therapeutics shares closed down 5.5% on Friday at $18.50, ending the first U.S. trading session of 2026 on a softer note. About 2.65 million shares changed hands. The pullback matters because 2026 is shaping up as a timing-driven year for the clinical-stage biotech, with investors focused on whether its lead Duchenne muscular dystrophy program can reach regulators on schedule and on what that path costs. Dyne said in December its Phase 1/2 DELIVER trial met its main biomarker goal, lifting dystrophin — a muscle protein missing in Duchenne —
4 January 2026
·
Dyne Therapeutics (DYN) stock slides today as biotech wobbles — FDA clock back in focus

Dyne Therapeutics (DYN) stock slides today as biotech wobbles — FDA clock back in focus

NEW YORK, Jan 2, 2026, 3:19 PM ET — Regular session Dyne Therapeutics shares fell about 6% on Friday, giving back earlier gains in a volatile first session of 2026 for some biotech names. The Nasdaq-listed stock was down 6.1% at $18.36 in afternoon trading, after touching $20.90 at the high and $18.13 at the low. The move matters because it pulls Dyne back toward the $18.44 price of its December share sale, a reference point traders often watch after a dilutive financing. Dyne said that offering raised about $402.5 million in gross proceeds. The broader tape offered little help.
2 January 2026
··
Biggest Stock Losers Today in the U.S. (Dec. 10, 2025): DYN, SLM, KTB, WAY and More Slide as Fed Decision Looms

Biggest Stock Losers Today in the U.S. (Dec. 10, 2025): DYN, SLM, KTB, WAY and More Slide as Fed Decision Looms

U.S. stocks are trading in a holding pattern on Wednesday, December 10, 2025, as Wall Street waits for the Federal Reserve’s final interest‑rate decision of the year. Index moves are modest, but beneath the surface a cluster of mid‑cap names is posting double‑digit percentage declines, led by Dyne Therapeutics (DYN), SLM Corp (SLM), Kontoor Brands (KTB) and Waystar Holding (WAY). Investing.com+1 According to real‑time data from StockScan, the 10 biggest U.S. stock losers today by percentage move (among actively traded listed shares) are: StockScan Below is a breakdown of what’s driving today’s biggest losers, plus how they fit into the
10 December 2025
···········
Top US Stock Market Losers Today (December 9, 2025): HURA, Phreesia, Virgin Galactic, SLM, Gogo and More

Top US Stock Market Losers Today (December 9, 2025): HURA, Phreesia, Virgin Galactic, SLM, Gogo and More

The US stock market spent most of Tuesday, December 9, 2025 trading quietly ahead of this week’s Federal Reserve decision — but beneath the calm index surface, several individual stocks suffered brutal double‑digit losses. As of around 3:44 p.m. ET, live data from Public.com showed TuHURA Biosciences (HURA), Phreesia (PHR), Euda Health (EUDA), SLM Corp (SLM), Virgin Galactic (SPCE), Gogo (GOGO), Compass Minerals (CMP), Workhorse Group (WKHS), 3D Systems (DDD) and Dyne Therapeutics (DYN) among the steepest percentage decliners across US‑listed stocks. Public Below is a detailed look at what drove today’s biggest losers — and what analysts and companies
9 December 2025
··········
Dyne Therapeutics (DYN) Stock Slides After $300 Million Offering as Duchenne Trial Data Drives Bullish Street Targets

Dyne Therapeutics (DYN) Stock Slides After $300 Million Offering as Duchenne Trial Data Drives Bullish Street Targets

December 9, 2025 — Dyne Therapeutics, Inc. (NASDAQ: DYN) shares were volatile on Tuesday, giving back part of a recent rally even as Wall Street responded positively to new clinical data and raised price targets on the neuromuscular‑disease biotech. In early afternoon U.S. trading, Dyne stock was changing hands around $19.15, down roughly 14% on the day after opening near $21.41 and moving in a range between about $19 and $22. The pullback follows a sharp advance on Monday, when the shares jumped high‑single‑digits after the company released detailed positive Phase 1/2 results from its DELIVER trial in Duchenne muscular
9 December 2025
··

Stock Market Today

Costco stock price retakes $1,000 — what traders are watching before Monday

Costco stock price retakes $1,000 — what traders are watching before Monday

7 February 2026
Costco closed Friday up 1.2% at $1,001.16, regaining the $1,000 level as about 2.36 million shares changed hands. January net sales rose 9.3% to $21.33 billion, with comparable sales up 7.1% and online sales surging 34.4%. Wells Fargo raised its price target to $950, maintaining a neutral rating. The next earnings call is set for March 5.
Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

7 February 2026
Johnson & Johnson shares rose 0.9% to $239.99 Friday after a New Jersey appeals court disqualified Beasley Allen from state talc cases, citing improper coordination with a former J&J attorney. The ruling affects about 3,600 state lawsuits, while a related federal motion is pending. J&J also reported early 12-month pilot data for its investigational AFib device at a cardiology meeting.
Go toTop